Can a targeted drug make immunotherapy work better for lung cancer?

NCT ID NCT05782361

Ongoing Disease control Sponsor: Institute of Cancer Research, United Kingdom Source: ClinicalTrials.gov ↗

First seen Apr 29, 2026 · Last updated May 24, 2026 · Updated 3 times

Summary

This early-stage study tests two drugs together—tepotinib and pembrolizumab—in people with advanced non-small cell lung cancer. The goal is to see if adding tepotinib can help pembrolizumab work better, especially in tumors that don't respond well to immunotherapy alone. About 19 adults with or without a specific MET gene mutation will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

DDU, Royal Marsden Hospital NHS Foundation Trust

Sutton, Surrey, SM2 5PT, United Kingdom
Lung Unit, Royal Marsden Hospital NHS Foundation Trust

London, SW3 6JJ, United Kingdom
The Christie NHS Foundation Trust

Manchester, M20 4BX, United Kingdom
University College London Hospitals NHS Foundation Trust

London, NW1 2BU, United Kingdom

Conditions

Explore the condition pages connected to this study.

ADVANCED CANCER NON-SMALL CELL LUNG CANCER NON-SMALL CELL LUNG CANCER